In recent years, Immune checkpoint inhibitors including programmed cell death-1 (PD-1) inhibitors and programmed cell death-Ligand (PD-1) 1, PD-L1) inhibitors have achieved good clinical efficacy and safety in patients with advanced HCC [20]. This evidence concerns the gene RPL17 and hepatocellular carcinoma.